February 28, 2017

According to a study published in The Lancet Oncology, using a genomic test that looks at 50 genes could prevent chemotherapy in up to 40 percent of women with breast cancer. The use of a genomic test that analyzes 50 genes could prevent chemotherapy (QT) in up to 40 percent of women suffering from HER2-positive […]

Approximately 50% of Epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) patients treated with EGFR tyrosine kinase inhibitors (TKIs) will acquire resistance by the T790M mutation. Osimertinib is the standard of care in this situation. The present study assesses the efficacy of osimertinib when T790M status is determined in circulating cell-free tumour